Genotype-based frequencies and therapeutic doses
| SNP alleles . | No. (%) . | Mean therapeutic dose (SD), mg/day . |
|---|---|---|
| CYP2C9, WT / WT | 58 (63) | 6.1 (2.5) |
| CYP2C9*2 / WT | 17 (18) | 5.3 (2.3) |
| CYP2C9*2 /CYP2C9*2 | 2 (2) | 4.3 (2.4) |
| CYP2C9*3 / WT | 11 (12) | 3.3 (1.0) |
| CYP2C9*2 / CYP2C9*3 | 4 (4) | 2.6 (0.8) |
| CYP2C9*3 / CYP2C9*3 | 0 | — |
| VKORC1 | ||
| VKORC1 B / B | 45 (49) | 6.6 (2.5) |
| VKORC1 A / B | 37 (40) | 4.5 (2.0) |
| VKORC1 A / A | 10 (11) | 3.8 (1.7) |
| SNP alleles . | No. (%) . | Mean therapeutic dose (SD), mg/day . |
|---|---|---|
| CYP2C9, WT / WT | 58 (63) | 6.1 (2.5) |
| CYP2C9*2 / WT | 17 (18) | 5.3 (2.3) |
| CYP2C9*2 /CYP2C9*2 | 2 (2) | 4.3 (2.4) |
| CYP2C9*3 / WT | 11 (12) | 3.3 (1.0) |
| CYP2C9*2 / CYP2C9*3 | 4 (4) | 2.6 (0.8) |
| CYP2C9*3 / CYP2C9*3 | 0 | — |
| VKORC1 | ||
| VKORC1 B / B | 45 (49) | 6.6 (2.5) |
| VKORC1 A / B | 37 (40) | 4.5 (2.0) |
| VKORC1 A / A | 10 (11) | 3.8 (1.7) |
SD indicates standard deviation; WT, wild type; CYP2C9, cytochrome P450 2C9; —, not available; and VKORC1, vitamin K epoxide reductase complex 1.